Study on the bioactivity against hematologic malignancies and theoretical binding mechanism of a novel PI3K inhibitor JN-65

KE Ke; JIANG Wenli; WANG Yu; ZHU Jingyu; JIN Jian

doi:10.11665/j.issn.1000-5048.20190405

Journal of China Pharmaceutical University > 2019 > 50(4): 410-416. > DOI: 10.11665/j.issn.1000-5048.20190405

KE Ke, JIANG Wenli, WANG Yu, ZHU Jingyu, JIN Jian. Study on the bioactivity against hematologic malignancies and theoretical binding mechanism of a novel PI3K inhibitor JN-65[J]. Journal of China Pharmaceutical University, 2019, 50(4): 410-416. DOI: 10.11665/j.issn.1000-5048.20190405

Citation:

PDF (2608 KB)

Study on the bioactivity against hematologic malignancies and theoretical binding mechanism of a novel PI3K inhibitor JN-65

More Information

Graphical Abstract

Abstract

Abstract

The PI3K signaling pathway is frequently over-expressed in a variety of hematologic malignancies, so the development of PI3K inhibitors for the treatment of hematologic malignancies has broad application prospects. In this study, a novel PI3K inhibitor, JN-65, was identified through the investigation effects in the inhibition to hematologic malignancies. By MTT assays, JN-65 was found to effectively suppress the proliferation of hematologic malignancies, especially leukemia cell lines. The cell-free enzymatic studies demonstrated that JN-65 cloud inhibit PI3K and specifically inhibited PI3Kγ at low micromolar concentrations. Western blot confirmed that JN-65 could effectively inhibit the PI3K/Akt signaling pathway and the flow cytometry assays verified that JN-65 could induce the apoptosis of tumor cells through the suppression of PI3K signaling pathway. Finally, the molecular docking simulation method was used to explore the interaction between JN-65 and PI3K, and the inhibition mechanism of PI3K was revealed at the molecular level. In general, JN-65 would be a potential PI3K inhibitor for the treatment of hematologic malignancies.
- PI3K inhibitor,
- JN-65,
- hematologic malignancies,
- leukemia,
- molecular docking

FullText(HTML)

References (22)

References

[1]	Zhu JY,Wang M,Cao BY,et al.Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma[J].Curr Med Chem,2014,21(27):3173-3187.
[2]	Naymagon L,Abdul-Hay M.Novel agents in the treatment of multiple myeloma:a review about the future[J].J Hematol Oncol,2016,9(1):52.
[3]	Zhu JY,Hou TJ,Mao XL.Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies[J].Drug Discov Today,2015,20(8):988-994.
[4]	Cantley LC.The phosphoinositide 3-kinase pathway[J].Science,2002,296(5573):1655-1657.
[5]	Fruman DA,Rommel C.PI3K and cancer:lessons,challenges and opportunities[J].Nat Rev Drug Discov,2014,13(2):140-156.
[6]	Carracedo A,Pandolfi PP.The PTEN-PI3K pathway:of feedbacks and cross-talks[J].Oncogene,2008,27(41):5527-5541.
[7]	Liu PX, Cheng HL, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer[J].Nat Rev Drug Discov,2009,8(8):627-644.
[8]	Yuan TL,Cantley LC.PI3K pathway alterations in cancer:variations on a theme[J].Oncogene,2008,27(41):5497-5510.
[9]	Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis[J].Adv Cancer Res,2009,102:19-65.
[10]	Fresno Vara JA,Casado E,de Castro J,et al.PI3K/Akt signalling pathway and cancer[J].Cancer Treat Rev,2004,30(2):193-204.
[11]	Xin MH,Zhang SQ.Advances in PI3Kδ selective inhibitors[J].J China Pharm Univ(中国药科大学学报),2016,47(5):503-510.
[12]	Hennessy BT,Smith DL,Ram PT,et al.Exploiting the PI3K/AKT pathway for cancer drug discovery[J].Nat Rev Drug Discov,2005,4(12):988-1004.
[13]	Lien EC,Dibble CC,Toker A.PI3K signaling in cancer:beyond AKT[J].Curr Opin Cell Biol,2017,45:62-71.
[14]	Silva A,Yunes JA,Cardoso BA,et al.PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability[J].J Clin Invest,2008,118(11):3762-3774.
[15]	Min YH,Eom JI,Cheong JW,et al.Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia:its significance as a prognostic variable[J].Leukemia,2003,17(5):995-997.
[16]	Hyun T,Yam A,Pece S,et al.Loss of PTEN expression leading to high Akt activation in human multiple myelomas[J].Blood,2000,96(10):3560-3568.
[17]	Miller BW,Przepiorka D,de Claro RA,et al.FDA approval:idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma[J].Clin Cancer Res,2015,21(7):1525-1529.
[18]	Blair HA.Duvelisib:first global approval[J].Drugs,2018,78(17):1847-1853.
[19]	Miller MS,Maheshwari S,McRobb FM,et al.Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design[J].Bioorg Med Chem,2017,25(4):1481-1486.
[20]	Zhang XX,Vadas O,Perisic O,et al.Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhi-bitory mechanism[J].Mol Cell,2011,41(5):567-578.
[21]	Somoza JR,Koditek D,Villaseñor AG,et al.Structural,biochemical,and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ[J].J Biol Chem,2015,290(13):8439-8446.
[22]	Pecchi S,Ni ZJ,Han W,et al.Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K[J].Bioorg Med Chem Lett,2013,23(16):4652-4656.

Cited By

Cited by

Periodical cited type(2)

1.	郁莉，蒋颖敏，许磊，朱景宇. 分子对接与分子动力学模拟法探究PI3Kδ/度维利塞(Duvelisib)的选择性结合. 化学研究与应用. 2022(02): 341-348 .
2.	蔡燕飞，陈蕴，史劲松，金坚. 抗肿瘤药物体外药效学评价结合细胞生物学实验教学促进教研融合. 实验室研究与探索. 2020(08): 192-195 .

Other cited types(0)

Get Citation

PDF

XML

Article views (544) PDF downloads (1590) Cited by(2)

Turn off MathJax

Article Contents

Abstract

References

Study on the bioactivity against hematologic malignancies and theoretical binding mechanism of a novel PI3K inhibitor JN-65

Abstract

References

Cited by

Periodical cited type(2)

Other cited types(0)

Catalog

Export File

Citation

Format

Content